May 1 (Reuters) - Emergent BioSolutions ( EBS ) said on

Wednesday that it would cut about 300 jobs across all areas of

the company and shut down several manufacturing facilities as

part of a restructuring plan.

Emergent has been seeking to cut costs and pivot away from

its contract manufacturing business due to sluggish demand.

It cut its workforce by 400 employees last year and

scaled back operations at some its facilities to focus on core

products such as overdose reversal nasal spray Narcan.